Understanding how SORL 1-retromer affects Alzheimer's disease
Official title: SORL 1-Retromer Biology in the Pathogenesis of Alzheimers Disease
Funded at Brigham and Women's Hospital · NIH-11074222 · Data updated 2026-11-12
This study is looking at how changes in a specific gene related to Alzheimer's disease might affect the way proteins move in brain cells, with the goal of finding out which patients could benefit from new treatments that help fix these issues.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 30, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,858,368 |
| NIH project number | 1RF1AG091846-01 |
| Project ID | NIH-11074222 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with a family history of Alzheimer's disease or those identified with pathogenic mutations in the SORL 1 gene.
✕Less likely to help
Patients without genetic mutations linked to Alzheimer's disease or those with other forms of dementia may not benefit from this research.
What this research studies
This research investigates the role of the SORL 1-retromer complex in Alzheimer's disease by examining how genetic variations in the SORL 1 gene contribute to the disease's development. The study focuses on understanding the biological mechanisms that lead to neurodegeneration, particularly how mutations disrupt the normal trafficking of proteins within neurons. By identifying pathogenic mutations, the research aims to determine which patients may benefit from therapies designed to restore proper protein function and trafficking.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for Alzheimer's disease that target the underlying genetic causes.
How similar studies have gone: Previous research has shown promising results in understanding genetic factors in Alzheimer's disease, making this approach both relevant and potentially impactful.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Petsko, Gregory a — Brigham and Women's Hospital
- Study coordinator: Petsko, Gregory a
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Cognitive SuperAging: Exploring why some octogenarians stay sharp in memory
This NIH grant studies why a small group of people aged 80+ keep memory skills as good as much younger people, hoping to understand how to protect memory as we age.
-
CLU's role in Alzheimer's disease pathogenesis
Researchers are studying how the CLU gene may drive brain changes in Alzheimer's disease and how targeting CLU could lead to safer treatments.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.